Please assess the completion status of the following clinical trial:

Trial Title: Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years~2. Positive SARS-CoV-2 test by PCR (polymerase chain reaction) or other diagnostic method within the past 7 days~3. Admission to hospital with respiratory symptoms of COVID-19 requiring hospital care and oxygen supplementation (≤ 8L/min)~4. Respiratory symptom onset no more than 7 days prior to hospital arrival~5. Informed consent from the subject or the subject's personal legal representative or a professional legal representative must be available~Exclusion Criteria:~1. Unable to screen, randomize and administer study drug within 48 hours from arrival to hospital~2. Systemic corticosteroid, baricitinib or tofacitinib (or other JAK-STAT signalling pathway inhibitors) therapy within 7 days prior to arrival to hospital or planned for the next days~3. Known hypersensitivity or contraindication to natural or recombinant IFN-beta-1a or its excipients, or to dexamethasone or its excipients~4. Currently receiving IFN-beta-1a therapy~5. Home assisted ventilation (via tracheotomy or non-invasive) except for Continuous Positive Airway Pressure (CPAP) / Bilevel Positive Airway Pressure (BIPAP) used only for sleep-disordered breathing~6. Participation in another concurrent interventional pharmacotherapy trial during the study period~7. Decision to withhold life-sustaining treatment; patient not committed to full support (except DNR after cardiac arrest only)~8. Woman known to be pregnant, lactating or with a positive pregnancy test (urine or serum test)~9. Subject is not expected to survive for 24 hours~10. Subject has liver failure (Child-Pugh grade C)~11. Any clinical condition that in the opinion of the attending clinician or Investigator would present a risk for the subject to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV IFN beta-1a (Type: EXPERIMENTAL): Patients receiving active drug: will receive two separate bolus injections one containing IFN-beta -1a and another injection containing Saline.
- IV Dexamethasone (Type: ACTIVE_COMPARATOR): Patients receiving active comparator: will receive two separate bolus injections one containing saline and another injection containing Dexamethasone.

Based on this trial design, predict the completion outcome and termination type (if applicable).